<DOC>
	<DOCNO>NCT01253213</DOCNO>
	<brief_summary>The purpose study determine whether BR55 able identify area VEGFR2 expression human prostate ultrasound molecular imaging . This compare histopathology analysis ( location base expression VEGFR2 tissue specimen determine immuno-histochemistry , IHC ) .</brief_summary>
	<brief_title>BR55 Prostate Cancer : Exploratory Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male patient , age ≥ 40 year old Has histology proven focal prostate cancer lesion The patient already schedule prostatectomy earlier 3 day late 15 day BR55 administration Provides write Informed Consent willing comply protocol requirement Has body weight great 95 kg ( weight limitation require order maintain active component drug 100μg ) accord indication EMEA guideline M3 type study Has document acute prostatitis urinary tract infection Is know suffer stable angina pectoris and/or proven coronary disease , symptoms suspicious coronary disease With history clinically unstable cardiac condition include class III/IV cardiac failure righttoleft shunt Has severe cardiac rhythm disorder within last 7 day Has severe pulmonary hypertension ( pulmonary artery pressure &gt; 90 mmHg ) uncontrolled systemic hypertension respiratory distress syndrome Has receive prostate biopsy procedure within 30 day admission study Has medical condition circumstance would significantly decrease chance obtain reliable data , achieve study objective , complete study . Is determined Investigator patient clinically unsuitable study . Is incapable understanding language information patient give Participation concurrent clinical trial another trial investigational compound within past 30 day ;</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Ultrasound molecular imaging</keyword>
	<keyword>Contrast agent</keyword>
	<keyword>BR55</keyword>
	<keyword>VEGFR2</keyword>
</DOC>